JP5587950B2 - 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用 - Google Patents

臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用 Download PDF

Info

Publication number: JP5587950B2
Authority: JP; Japan
Prior art keywords: parapoxvirus; fibrosis; cells; liver; treatment
Prior art date: 2000-07-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP2012145847A

Other languages

English (en)

Japanese (ja)

Other versions

JP2012214492A (ja

Inventor

クラウディア・ヒルト−ディートリッヒ

トビアス・シュラップ

アンゲラ・ジークリング

アンドレアス・クノール

オラフ・ヴェーバー

グトルン・タイス

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aicuris GmbH and Co KG

Original Assignee

Aicuris GmbH and Co KG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-11

Filing date

2012-06-28

Publication date

2014-09-10

2012-06-28 Application filed by Aicuris GmbH and Co KG filed Critical Aicuris GmbH and Co KG

2012-11-08 Publication of JP2012214492A publication Critical patent/JP2012214492A/ja

2014-09-10 Application granted granted Critical

2014-09-10 Publication of JP5587950B2 publication Critical patent/JP5587950B2/ja

2021-07-11 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

241000700639 Parapoxvirus Species 0.000 title claims abstract description 31
206010016654 Fibrosis Diseases 0.000 title claims abstract description 21
230000004761 fibrosis Effects 0.000 title claims abstract description 18
210000000056 organ Anatomy 0.000 title claims description 12
241000283898 Ovis Species 0.000 title description 11
239000003814 drug Substances 0.000 claims abstract description 13
238000011282 treatment Methods 0.000 claims description 21
210000004027 cell Anatomy 0.000 claims description 19
241000282412 Homo Species 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 11
230000002265 prevention Effects 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
241000283690 Bos taurus Species 0.000 claims description 2
241001494479 Pecora Species 0.000 claims description 2
210000005260 human cell Anatomy 0.000 claims description 2
238000002955 isolation Methods 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 15
102000008186 Collagen Human genes 0.000 abstract description 13
108010035532 Collagen Proteins 0.000 abstract description 13
229920001436 collagen Polymers 0.000 abstract description 13
238000002360 preparation method Methods 0.000 abstract description 10
230000009466 transformation Effects 0.000 abstract description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
210000004024 hepatic stellate cell Anatomy 0.000 abstract description 7
201000010099 disease Diseases 0.000 abstract description 5
230000002828 effect on organs or tissue Effects 0.000 abstract 1
230000003449 preventive effect Effects 0.000 abstract 1
241001465754 Metazoa Species 0.000 description 32
208000019425 cirrhosis of liver Diseases 0.000 description 30
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 30
210000002966 serum Anatomy 0.000 description 21
210000004185 liver Anatomy 0.000 description 14
241000700605 Viruses Species 0.000 description 13
239000000243 solution Substances 0.000 description 13
238000002474 experimental method Methods 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
241000700159 Rattus Species 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
230000007882 cirrhosis Effects 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
239000002775 capsule Substances 0.000 description 6
239000012634 fragment Substances 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
238000000034 method Methods 0.000 description 6
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
108010082126 Alanine transaminase Proteins 0.000 description 5
101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 5
102000016901 Glutamate dehydrogenase Human genes 0.000 description 5
238000008050 Total Bilirubin Reagent Methods 0.000 description 5
239000002609 medium Substances 0.000 description 5
230000000069 prophylactic effect Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
239000006145 Eagle's minimal essential medium Substances 0.000 description 4
230000000434 anti-fibrogenic effect Effects 0.000 description 4
230000003510 anti-fibrotic effect Effects 0.000 description 4
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
230000006978 adaptation Effects 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000003352 fibrogenic effect Effects 0.000 description 3
210000003494 hepatocyte Anatomy 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
210000005228 liver tissue Anatomy 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000013223 sprague-dawley female rat Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
CRCWUBLTFGOMDD-UHFFFAOYSA-N 7-ethoxyresorufin Chemical compound C1=CC(=O)C=C2OC3=CC(OCC)=CC=C3N=C21 CRCWUBLTFGOMDD-UHFFFAOYSA-N 0.000 description 2
108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
206010067125 Liver injury Diseases 0.000 description 2
YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 2
108091027544 Subgenomic mRNA Proteins 0.000 description 2
229940087168 alpha tocopherol Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
238000013245 carbon tetrachloride model Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
230000008021 deposition Effects 0.000 description 2
238000001784 detoxification Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000011866 long-term treatment Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000013425 morphometry Methods 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
210000004738 parenchymal cell Anatomy 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
229960000984 tocofersolan Drugs 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
239000002076 α-tocopherol Substances 0.000 description 2
235000004835 α-tocopherol Nutrition 0.000 description 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
229940123457 Free radical scavenger Drugs 0.000 description 1
-1 GGT Proteins 0.000 description 1
206010019668 Hepatic fibrosis Diseases 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108010002885 Polygeline Proteins 0.000 description 1
208000013200 Stress disease Diseases 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
FXAGBTBXSJBNMD-UHFFFAOYSA-N acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FXAGBTBXSJBNMD-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
231100000439 acute liver injury Toxicity 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000002300 anti-fibrosis Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
230000037319 collagen production Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
231100000753 hepatic injury Toxicity 0.000 description 1
210000000208 hepatic perisinusoidal cell Anatomy 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229960003350 isoniazid Drugs 0.000 description 1
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
210000001865 kupffer cell Anatomy 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000018191 liver inflammation Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000010606 normalization Methods 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
238000000053 physical method Methods 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229960004250 polygeline Drugs 0.000 description 1
239000011148 porous material Substances 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
BXSDMMPOQRECKB-UHFFFAOYSA-N sodium;chloro-(4-methylphenyl)sulfonylazanide;hydrate Chemical compound O.[Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 BXSDMMPOQRECKB-UHFFFAOYSA-N 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000000352 storage cell Anatomy 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000004448 titration Methods 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
102000014898 transaminase activity proteins Human genes 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24261—Methods of inactivation or attenuation
- C12N2710/24264—Methods of inactivation or attenuation by serial passage

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Addiction (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Dermatology (AREA)
Neurology (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Biochemistry (AREA)
Neurosurgery (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

JP2012145847A 2000-07-11 2012-06-28 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用 Expired - Lifetime JP5587950B2 (ja)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DE10033581.0		2000-07-11
DE10033581		2000-07-11
DE10122233A DE10122233A1 (de)	2000-07-11	2001-05-08	Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
DE10122233.5		2001-05-08

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2002508473A Division JP5106736B2 (ja)	2000-07-11	2001-07-11	臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2014124405A Division JP5950964B2 (ja)	2000-07-11	2014-06-17	臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用

Publications (2)

Publication Number	Publication Date
JP2012214492A JP2012214492A (ja)	2012-11-08
JP5587950B2 true JP5587950B2 (ja)	2014-09-10

Family

ID=7648485

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2012145847A Expired - Lifetime JP5587950B2 (ja)	2000-07-11	2012-06-28	臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用
JP2014124405A Expired - Lifetime JP5950964B2 (ja)	2000-07-11	2014-06-17	臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2014124405A Expired - Lifetime JP5950964B2 (ja)	2000-07-11	2014-06-17	臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用

Country Status (14)

Country	Link
JP (2)	JP5587950B2 (de)
KR (1)	KR100845643B1 (de)
CN (1)	CN101444539B (de)
AT (1)	ATE445413T1 (de)
BR (1)	BRPI0112411B8 (de)
DE (2)	DE10122233A1 (de)
DK (1)	DK1303302T3 (de)
DO (1)	DOP2001000210A (de)
EC (1)	ECSP034420A (de)
ES (1)	ES2332355T3 (de)
PE (1)	PE20020218A1 (de)
PT (1)	PT1303302E (de)
SV (1)	SV2002000527A (de)
ZA (1)	ZA200300276B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102015111756A1 (de) *	2015-07-20	2017-01-26	Eberhard Karls Universität Tübingen Medizinische Fakultät	Rekombinanter Orf-Virus-Vektor
AU2017221592A1 (en)	2016-02-16	2018-10-04	Osaka University	Pharmaceutical composition for use in treating fibrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4405841C1 (de) *	1994-02-23	1995-01-05	Mayr Anton Prof Dr Med Vet Dr	Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK0885013T3 (da) *	1996-04-15	2001-11-05	Anton Prof Dr Med Vet Dr Mayr	Anvendelse af multipotente paramunitetsinducere fra svækkede, ikke-immunogene poxvirus eller parapoxvirus til fremstilling af lægemidler

2001
- 2001-05-08 DE DE10122233A patent/DE10122233A1/de not_active Withdrawn
- 2001-07-10 PE PE2001000681A patent/PE20020218A1/es not_active Application Discontinuation
- 2001-07-11 KR KR1020037000310A patent/KR100845643B1/ko not_active Expired - Fee Related
- 2001-07-11 SV SV2001000527A patent/SV2002000527A/es not_active Application Discontinuation
- 2001-07-11 PT PT01965110T patent/PT1303302E/pt unknown
- 2001-07-11 DO DO2001000210A patent/DOP2001000210A/es unknown
- 2001-07-11 DK DK01965110.8T patent/DK1303302T3/da active
- 2001-07-11 CN CN200810149856.XA patent/CN101444539B/zh not_active Expired - Lifetime
- 2001-07-11 BR BRPI0112411-0 patent/BRPI0112411B8/pt not_active IP Right Cessation
- 2001-07-11 DE DE50115181T patent/DE50115181D1/de not_active Expired - Lifetime
- 2001-07-11 AT AT01965110T patent/ATE445413T1/de active
- 2001-07-11 ES ES01965110T patent/ES2332355T3/es not_active Expired - Lifetime
2003
- 2003-01-10 ZA ZA200300276A patent/ZA200300276B/en unknown
- 2003-01-10 EC EC2003004420A patent/ECSP034420A/es unknown
2012
- 2012-06-28 JP JP2012145847A patent/JP5587950B2/ja not_active Expired - Lifetime
2014
- 2014-06-17 JP JP2014124405A patent/JP5950964B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2014196329A (ja)	2014-10-16
DE10122233A1 (de)	2002-01-24
BR0112411A (pt)	2003-05-27
SV2002000527A (es)	2002-10-24
ES2332355T3 (es)	2010-02-03
JP2012214492A (ja)	2012-11-08
JP5950964B2 (ja)	2016-07-13
KR20030019562A (ko)	2003-03-06
ZA200300276B (en)	2004-04-13
PT1303302E (pt)	2009-11-11
CN101444539A (zh)	2009-06-03
BRPI0112411B1 (pt)	2018-02-27
DOP2001000210A (es)	2002-12-15
ECSP034420A (es)	2003-03-10
PE20020218A1 (es)	2002-05-19
DE50115181D1 (de)	2009-11-26
CN101444539B (zh)	2016-07-06
DK1303302T3 (da)	2010-02-08
KR100845643B1 (ko)	2008-07-10
BRPI0112411B8 (pt)	2021-05-25
ATE445413T1 (de)	2009-10-15

Legal Events

Date	Code	Title	Description
2012-07-28	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120727
2012-07-28	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120727
2013-12-18	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131217
2014-03-15	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140314
2014-03-20	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140319
2014-04-17	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140416
2014-04-22	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140421
2014-05-17	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140516
2014-05-22	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140521
2014-06-18	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140617
2014-06-27	TRDD	Decision of grant or rejection written
2014-07-02	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140701
2014-07-31	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140724
2014-08-01	R150	Certificate of patent or registration of utility model	Ref document number: 5587950 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2017-08-01	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2018-07-31	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-07-30	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2020-07-27	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-07-11	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
CN102858959B (zh)	2016-02-24	溶瘤弹状病毒
EA034195B1 (ru)	2020-01-16	Штаммы бактериофага, способные вызывать литическую инфекцию адгезивно-инвазивного штамма escherichia coli, и их применение
JP5106736B2 (ja)	2012-12-26	臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用
JP5950964B2 (ja)	2016-07-13	臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用
CN101137748A (zh)	2008-03-05	粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用
JP6875745B2 (ja)	2021-05-26	線維化を治療するための医薬組成物
HK1060050A (en)	2004-07-30	Use of strains of the parapox ovis virus against organ fibrosis
Tonew et al.	1995	Replication and persistence of coxsackieviruses B3 in human fibroblasts
CN1909923B (zh)	2012-10-03	基于减毒的兔粘液瘤病毒的单副免疫诱导物
CN100451109C (zh)	2009-01-14	重组1型单纯疱疹病毒及制备方法和应用
CN118526483A (zh)	2024-08-23	一种天然植物来源的联苯多酚化合物在制备治疗疱疹性疾病的药物中的应用
Weissenbacher et al.	1973	Sensitivity of human conjunctival tissue cultures to adenovirus 8, herpes simplex and vaccinia viruses. Induction of resistance by an interferon inducer
US20080305129A1 (en)	2008-12-11	Highly Attenuated Pox Virus Strains, Method for the Production Thereof and the Use Thereof as Paramunity Inducers or For Producing Vector Vaccines
CN119548506A (zh)	2025-03-04	雷替曲塞在治疗痘病毒感染所致疾病中的应用
CN1570091A (zh)	2005-01-26	重组1型单纯疱疹病毒及其制备方法和应用
Kriek	2003	The oncolytic properties of two newcastle disease virus strains
Kriek	0	IOUOnivIers~ ityIF~ ree~ St~ ate~~~~~~~~~ 34300002088221 Universiteit Vrystaat The Oncolytic Properties of Two Newcastle Disease Virus Strains.
CN101082042A (zh)	2007-12-05	人工改造的缺陷型人3型腺病毒的应用